Genomics of Resistance to Targeted Therapies

has led to transformative breakthroughs in the last decade, with introduction of agents targeting the B cell receptor (BCR) signaling pathway through BTK and phosphatidylinositol 3-kinase (PI3K), as well as agents inhibiting Bcl2. In relapsed8-14 patients as well as those who are previously untreated,15-19 these novel agents have demonstrated important clinical efficacy. Although these novel agents are superior to chemoimmunotherapy in higher risk disease, some patients fail to respond or relapse after treatment, especially those with high genomic risk disease. Therefore, there is a